Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03358134
Other study ID # AMC__45246_MoA_aIL17
Secondary ID 2013-002709-79
Status Completed
Phase Phase 3
First received February 12, 2014
Last updated November 29, 2017
Start date March 2014
Est. completion date October 2017

Study information

Verified date November 2017
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the mechanism of action on target tissue level of anti Interleukine-17 (anti-IL-17) an therapy in peripheral spondyloarthritis.

Patients will be treated with anti-IL-17 therapy (secukinumab) for 12 weeks and with a 2 year extension period thereafter.

At week 0 and 12 peripheral blood, synovial tissue and skin will be analysed with different techniques, including immunohistochemistry, RNA analysis and tissue culture to assess the effect of the therapy on inflammatory pathways.


Description:

Background of the study:

Spondyloarthritis is the second most frequent form of chronic inflammatory arthritis with a prevalence of 0.5%. It effects mainly young adults and leads to major functional handicap due to inflammation of axial and peripheral joints as well as progressive ankylosis and structural damage.

In the late nineties Tumor Necrosis Factor (TNF) blockade was introduced as a successful treatment, but: only 50% responds well and tolerates, a-TNF does not halt the structural damage and TNF blockade does not induce long lasting remission as almost all patients relapse within a few weeks after interruption of the treatment. There is thus a high unmet need for alternatives.

The rationale for anti-IL17 therapy is based on various auto-inflammatory and auto immune models, preliminary efficacy data in psoriasis and Rheumatoid arthritis (RA) and an association of SpA with Interleukin 23 Receptor (IL23R) single nucleotide polymorphism (SNP).

Efficacy data on anti-IL17 shows that it is a highly effective treatment for signs and symptoms in SpA, moreover sub-analysis of the anti-TNF naïve patients shows the same trend.

Objective of the study:

To assess molecular and cellular effects of the treatment on the synovium.

Secondary:

To compare which molecular and cellular disease pathways are affected by IL-17 blockade and not by TNF blockade and thereby identify molecular biomarkers which may help to determine which patients may benefit form this treatment in comparison with anti-TNF treatment.

To assess wether AIN457 silences vessel wall inflammation (by means of 18F-FDG PET(positron emission tomography)/CT of the carotic arteries and aorta.

Study design:

Single centre, 12-week open label study in subjects with clinically active peripheral spondylarthritis, with open label extension up to 2 years. Synovial biopsies and 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (18F FDG) PET/CT of the aorta and carotid arteries will be obtained from patients before and after 12 weeks of treatment with secukinumab.

Study population:

Patients with a diagnosis of spondyloarthritis according to the European Spondyloarthropathy Study Group (ESSG) or Assess Spondyloarthritis to international Society (ASAS) criteria with at least one swollen knee or ankle joint.

Intervention :

Secukinumab (AIN457) by subcutaneous injections (weekly for the first 4 weeks and every 4 weeks thereafter).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 2017
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Male or non-pregnant/non-lactating females age 18-70

- Diagnosis of SpA according to ESSG criteria and/or ASAS criteria

- Active disease defined by =1 swollen and = 1 tender joint, and at least 1 swollen knee or ankle joint at baseline

Exclusion Criteria:

- Evidence for infectious or malignant process (on chest X ray/MRI etc)

- Patients taking opioid analgetics

- Previous IL-17 therapy exposure

- Previous use of cell-depleting therapies, biological immunomodulators (except for TNF blockade , as 25% may have been previously treated with 1 TNF blocking agent)

- Significant medical problems or diseases

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Secukinumab
anti IL17 therapy (subcutaneous)

Locations

Country Name City State
Netherlands Academic Medical Center Amsterdam Amsterdam Noord-Holland

Sponsors (2)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Novartis

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Biological changes induced by therapy on target tissue (synovium) Molecular changes of the synovium as measured by expression of several cytokines/chemokines by quantitative polymerase chain reaction (qPCR) as measured by a change in cytokine expression between baseline and week 12. week 0 and week 12
Primary Changes of cellular infiltrate in the target tissue (synovium) Changes in cell count measured by immunohistochemistry (on a 0-4 semi-quantitative analysis scale) week 0 and week 12
Secondary Adverse events Number of patients with adverse events as a measure of safety and tolerability between day0 and 2 yrs of treatment
Secondary Vessel wall inflammation Changes in Fludeoxyglucose (FDG18) PET/CT uptake in the vessel walls of the carotic arteries and aorta as measured by CT values week 0 and week 12
See also
  Status Clinical Trial Phase
Recruiting NCT04540432 - Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment N/A
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Recruiting NCT01216631 - Seronegative Oligoarthritis of the Knee Study (SOKS) Phase 2
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4
Active, not recruiting NCT03456206 - Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Completed NCT02436785 - Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? N/A
Withdrawn NCT00298012 - Methotrexate in the Treatment of Axial Spondyloarthritis Phase 4
Recruiting NCT02809781 - A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis Phase 2/Phase 3
Completed NCT02098694 - Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis N/A
Completed NCT00591201 - Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies Phase 2/Phase 3
Completed NCT03190603 - Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Phase 4
Completed NCT01604629 - Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Phase 4
Active, not recruiting NCT06402396 - Assessing Pain by the painDETECT Questionnaire (PDQ)
Completed NCT04709354 - Clinical and Dermoscopic Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriasis Patients' Nails